Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients wi...
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparisonLevels of 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL) at diagnosis were significantly correlated with length of survival in patients with ALSIn a previously reported Investigator Initiated Trial that studied the combination of subcutaneous low-dose interleukin 2 (LD IL-2) and CTLA-4 Ig, these biomarkers of survival were reduced from baseline HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measureme
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics (COYA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" MarketBeat
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent DirectorBusiness Wire
- ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOBusiness Wire
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
COYA
Earnings
- 3/16/26 - Miss
COYA
Sec Filings
- 4/9/26 - Form 4
- 4/9/26 - Form 3
- 4/2/26 - Form 8-K
- COYA's page on the SEC website